Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi Center, Prospective, Non Interventional (NI) Study of the Safety and Efficacy of Sunitinib in Chinese Patients With Progressive Advanced or Metastatic Well Differentiated Unresectable Pancreatic Neuroendocrine Tumors

NCT02282059 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02282059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02282059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi Center, Prospective, Non Interventional (NI) Study of the Safety and Efficacy of Sunitinib in Chinese Patients With Progressive Advanced or Metastatic Well Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
December 12, 2014
Completion date
December 12, 2022
Enrollment
100 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neuroendocrine tumors